Eli Lilly 2008 Annual Report Download - page 10

Download and view the complete annual report

Please find page 10 of the 2008 Eli Lilly annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 132

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132

PORTFOLIO AND PIPELINE
8
1For full prescribing information, please refer to individual product websites, which can be accessed from www.lilly.com.
Innovation at Lilly: The Portfolio and the Pipeline
Major Marketed Products1 (Dates indicate the year of fi rst global launch)
2005 Byetta® for type 2 diabetes
(exenatide) for use in combination with a thiazolidinedione (2007)
(in collaboration with Amylin Pharmaceuticals, Inc.)
2004 Alimta® for malignant pleural mesothelioma
(pemetrexed) for second-line treatment of non-squamous non-small cell lung cancer (NSCLC) (2004)
for fi rst-line treatment of non-squamous NSCLC (2008)
2004 Cymbalta® for major depressive disorder
(duloxetine) for diabetic peripheral neuropathic pain (2004)
for generalized anxiety disorder (2007)
for the maintenance treatment of major depressive disorder (2007)
for fi bromyalgia (2008)
(in collaboration with Quintiles Transnational Corp. in the U.S., Shionogi & Co. Ltd. in Japan,
and with Boehringer Ingelheim elsewhere in the world)
2004 Erbitux® for later-stage EGFR-expressing metastatic colorectal cancer
(cetuximab) for locally or regionally advanced squamous cell head and neck cancer (2006)
for later-stage recurrent or metastatic squamous cell head and neck cancer (2006)
(in collaboration with Bristol-Myers Squibb Co. in North America and Japan, and Merck KGaA
outside of North America and in Japan)
2004 Symbyax® for bipolar depression
(olanzapine/fl uoxetine)
2004 Yentreve® for stress urinary incontinence (outside the U.S.)
(duloxetine)
2003 Cialis® for erectile dysfunction
(tadalafi l) for once daily use (2007)
2003 Strattera® for attention-defi cit hyperactivity disorder (ADHD) in children, adolescents, and adults
(atomoxetine) for maintenance treatment of ADHD in children and adolescents (2008)
2002 Forteo® for treatment of men and postmenopausal women with osteoporosis who are at high
(teriparatide) risk for a fracture
for the treatment of glucocorticoid-induced osteoporosis (2008; Europe)
2001 Xigris® for severe sepsis in adult patients at high risk of death
(drotrecogin alfa
[activated])
1999 Actos® for type 2 diabetes
(pioglitazone) (in collaboration with Takeda outside the U.S.)
1998 Evista® for prevention of osteoporosis in postmenopausal women
(raloxifene) for treatment of osteoporosis in postmenopausal women (1999)
for reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis (2007)
for reduction in risk of invasive breast cancer in postmenopausal women at high risk for
invasive breast cancer (2007)
(in collaboration with Chugai Pharmaceutical Co., Ltd. in Japan)